http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 08 Sep 2026 08:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Vericel+to+Present+at+the+24th+Annual+Morgan+Stanley+Global+Healthcare+Conference+on+Tuesday%2C+September+15%2C+2026/27033747.html <p align="left">BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24^th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15^th, 2026.</p> <p>A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: <a href="https://www.globenewswire.com/Tracker?data=ke3TXgiH5F_hwKg0NPknmBAQ4wgVq_GRbvjsoifRqn83gSBVPBD_BK_BF2Q9LEKbtUJ3YPQ2Ri3ocnko5UXToKSAXLTeY2kTVDzyJDureXg=" rel="nofollow" target="_blank">http://investors.vcel.com</a>.</p> <p><strong>About Vericel Corporation<br /></strong>Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology http://www.streetinsider.com/Press+Releases/Vericel+to+Present+at+the+24th+Annual+Morgan+Stanley+Global+Healthcare+Conference+on+Tuesday%2C+September+15%2C+2026/27033747.html Tue, 08 Sep 2026 08:30:00 -0400 VCEL http://www.streetinsider.com/Globe+Newswire/Vericel+to+Present+at+the+24th+Annual+Morgan+Stanley+Global+Healthcare+Conference+on+Tuesday%2C+September+15%2C+2026/27033747.html <p align="left">BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24^th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15^th, 2026.</p> <p>A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: <a href="https://www.globenewswire.com/Tracker?data=ke3TXgiH5F_hwKg0NPknmBAQ4wgVq_GRbvjsoifRqn83gSBVPBD_BK_BF2Q9LEKbtUJ3YPQ2Ri3ocnko5UXToKSAXLTeY2kTVDzyJDureXg=" rel="nofollow" target="_blank">http://investors.vcel.com</a>.</p> <p><strong>About Vericel Corporation<br /></strong>Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology http://www.streetinsider.com/Globe+Newswire/Vericel+to+Present+at+the+24th+Annual+Morgan+Stanley+Global+Healthcare+Conference+on+Tuesday%2C+September+15%2C+2026/27033747.html Tue, 08 Sep 2026 08:30:00 -0400 VCEL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vericel+Corp++++++++++++++For%3A+Aug+12++Filed+by%3A+MCLAUGHLIN+KEVIN+F/26930308.html si-local-file:///var/storage/secattach/20260814/26930308.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vericel+Corp++++++++++++++For%3A+Aug+12++Filed+by%3A+MCLAUGHLIN+KEVIN+F/26930308.html Fri, 14 Aug 2026 16:10:00 -0400 O.00644714 VCEL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vericel+Corp++++++++++++++For%3A+Aug+12++Filed+by%3A+MCLAUGHLIN+KEVIN+F/26930308.html si-local-file:///var/storage/secattach/20260814/26930308.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vericel+Corp++++++++++++++For%3A+Aug+12++Filed+by%3A+MCLAUGHLIN+KEVIN+F/26930308.html Fri, 14 Aug 2026 16:10:00 -0400 O.00644714 VCEL http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vericel+Corp+++++++++++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26917406.html si-local-file:///var/storage/secattach/20260813/26917406.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vericel+Corp+++++++++++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26917406.html Thu, 13 Aug 2026 09:00:00 -0400 O.00644714 VCEL http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vericel+Corp+++++++++++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26917406.html si-local-file:///var/storage/secattach/20260813/26917406.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vericel+Corp+++++++++++++++++++++++++++Filed+by%3A+Soleus+Capital+Master+Fund%2C+L.P./26917406.html Thu, 13 Aug 2026 09:00:00 -0400 O.00644714 VCEL http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vericel+Corp+++++++++++++++++++++++++++Filed+by%3A+MCLAUGHLIN+KEVIN+F/26910253.html si-local-file:///var/storage/secattach/20260812/26910253.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vericel+Corp+++++++++++++++++++++++++++Filed+by%3A+MCLAUGHLIN+KEVIN+F/26910253.html Wed, 12 Aug 2026 09:47:00 -0400 O.00644714 VCEL http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vericel+Corp+++++++++++++++++++++++++++Filed+by%3A+MCLAUGHLIN+KEVIN+F/26910253.html si-local-file:///var/storage/secattach/20260812/26910253.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vericel+Corp+++++++++++++++++++++++++++Filed+by%3A+MCLAUGHLIN+KEVIN+F/26910253.html Wed, 12 Aug 2026 09:47:00 -0400 O.00644714 VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Press+Releases/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html <p><strong>News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.</strong></p><p align="left">RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2IMx0qWtx13tJF9Ka_5mncrORT3PZPW0Fi9NQfq4gMixdSkSXXfhw6qeolejlq4y3Ajes_j17h64Xx-uWeHrRuO36owTPIPOCx7YIjkkFOA=" rel="nofollow" target="_blank">Biotech Insider</a><strong> News Commentary - </strong>For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and http://www.streetinsider.com/Globe+Newswire/Cosmetic+Surgery%27s+Next+Debate%3A+Rebuild+Tissue%2C+Not+Fill+It/26905238.html Tue, 11 Aug 2026 15:35:51 -0400 AXGN AXGN CNXU KRYS KRYS NVST NVST VCEL VCEL